Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Hologic's average EBITDA Per Share Growth Rate was -16.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -16.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -9.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 9.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hologic was 143.30% per year. The lowest was -37.30% per year. And the median was 19.95% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Hologic 3-Year EBITDA Growth Rate Related Terms
FRA:HO1 vs WST, COO, ALGN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Hologic's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hologic 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hologic's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Hologic's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -16.60% mean?
Hologic (FRA:HO1) has a 3-Year EBITDA Growth Rate of -16.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hologic and its competitors.
Is Hologic's 3-Year EBITDA Growth Rate too high?
Hologic's current 3-Year EBITDA Growth Rate is -16.60%. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's 3-Year EBITDA Growth Rate compare to WST and COO?
Hologic's 3-Year EBITDA Growth Rate of -16.60% can be compared against companies in the Medical Devices & Instruments industry. The industry median 3-Year EBITDA Growth Rate is 8.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.35, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hologic and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hologic's current 3-Year EBITDA Growth Rate is -16.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (FRA:HO1) has a current 3-Year EBITDA Growth Rate of -16.60%. The stock's GF Value™ is €70.17, compared to a current price of €65.00 — trading 7.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -16.60%. Hologic's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Hologic (FRA:HO1), the current 3-Year EBITDA Growth Rate is -16.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hologic (FRA:HO1) Overvalued in 2026?
Based on GuruFocus' analysis, Hologic stock appears to be undervalued.
The current stock price of €65.00 is trading 7.4% below its estimated GF Value™ of €70.17.
Key valuation signals for FRA:HO1:
3-Year EBITDA Growth Rate: -16.60%
GF Value™: €70.17 vs. price of €65.00 (7.4% below fair value)
No single metric tells the full story. See the FRA:HO1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score
Get the complete analysis for FRA:HO1
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HO1 has been successfully added to your 
